Posted on 10423
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), Appili Therapeutics (TSX: APLI, OTCQX: APLIF) and Global Response Aid FZCO (GRA) today announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. REEQONUS™ is also known as Avigan® (favipiravir) Tablets, developed by FUJIFILM Toyama Chemical Co., Ltd.
Updated:
Share Article
AAA
Dr. Reddy’s Laboratories Canada Inc., on behalf of a consortium, has filed an application with Health Canada seeking authorisation for Reeqonus (favipiravir) tablets for the acute treatment of mild to moderate COVID-19 adult patients. “Dr. Reddy’s is working closely with Health Canada for an expedited review of the drug application as speed to market is essential”, VP and general manager Vinod Ramachandran said. “If approved, it will launch the product soon for COVID-19 patients in Canada,” he added.
Dr. Reddy’s Canada has filed the application on behalf of the consortium comprising Dr. Reddy’s Laboratories, Appili Therapeutics and Global Response Aid FZCO (GRA) under Health Canada’s interim order “respecting the importation, sale and advertising of drugs for use in relation to COVID-19.”
Dr Reddy s labs, its subsidiaries announces filing application for REEQONUS™ (favipiravir) Tablets
Hyderabad, Dec 22 (UNI) Dr. Reddy’s Laboratories Limited, along with its subsidiaries together referred to as “Dr. Reddy’s”, Appili Therapeutics and Global Response Aid FZCO (GRA) on Tuesday announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ (favipiravir) Tablets.
The REEQONUS™ (favipiravir) Tablets was for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.
REEQONUS™ is also known as Avigan® (favipiravir) Tablets developed by FUJIFILM Toyama Chemical Company Limited, the Pharma Company said in a release here.